CMPX on Nasdaq

Compass Therapeutics, Inc.

We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with PROKIDNEY CORP., ImageneBio, Inc. or Avalanche Biotechnologies, or pick any stock.

  • TickerCMPX on Nasdaq1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersBoston, Massachusetts1
  • Incorporated inDE2
  • Business address80 Guest Street, Boston, Ma 021352
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Our scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Our pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. We plan to advance our product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclin…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20254
-33.8%Return on equity4
-$49.2MFree cash flow4

Financial statements

Revenue54$0 in 2025
0$250.0K$500.0K$750.0K$1.0M2023: $0$020232024: $850.0K$850.0K20242025: $0$02025
Operating income678954-$72.8M in 2025+114% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$34.1M-$34.1M20192020: -$27.8M-$27.8M2020−18%2021: -$81.9M-$81.9M2021+194%2022: -$41.7M-$41.7M2022−49%2023: -$50.4M-$50.4M2023+21%2024: -$56.6M-$56.6M2024+12%2025: -$72.8M-$72.8M2025+29%
Net income678954-$66.5M in 2025+91% since 2019
-$100.0M-$75.0M-$50.0M-$25.0M02019: -$34.7M-$34.7M20192020: -$29.5M-$29.5M2020−15%2021: -$82.2M-$82.2M2021+179%2022: -$39.2M-$39.2M2022−52%2023: -$42.5M-$42.5M2023+8%2024: -$49.4M-$49.4M2024+16%2025: -$66.5M-$66.5M2025+35%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Licensing revenue$0$850.0K
Research and development$56.0M$42.3M
General and administrative$16.9M$15.1M
Total operating expenses$72.8M$57.5M
Loss from operations-$72.8M-$56.6M
Interest income$6.3M$7.2M
Net loss-$66.5M-$49.4M
Net loss per share - basic and diluted (in dollars per share)-$0.42-$0.36
Basic and diluted weighted average shares outstanding (in shares)157.7M shares137.4M shares
Unrealized gain on marketable securities$70.0K$173.0K
Comprehensive loss-$66.4M-$49.2M

Compare Compass Therapeutics, Inc. with another company

Leadership

Who has led Compass Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas J. Schuetz2020–2024
  2. Vered Bisker-Leib2024

President

  1. Vered Bisker-Leib2021
  2. Thomas J. Schuetz2024

Chief financial officer

  1. Barry Shin2024–now

Chief operating officer

  1. Vered Bisker-Leib2020–2023
2025
Board members and other officers (19)

Former names

  • Olivia Ventures, Inc.May 30, 2018 to Jun 8, 20202

Timeline

  1. Jan 10, 2024New chief executive Vered Bisker-Leib becomes CEO12
  2. Jun 23, 2020New chief executive Thomas J. Schuetz becomes CEO13

Filings

269 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 49 major events, 115 insider forms, 41 large holders, 44 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Sep 25, 20264 EDGAR
  3. Sep 22, 20268-K EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 7, 2026SCHEDULE 13G EDGAR
  6. Aug 6, 202610-Q EDGAR
  7. Aug 6, 20268-K EDGAR
  8. Jul 1, 20268-K EDGAR
  9. Jun 23, 20268-K EDGAR
  10. Jun 11, 20268-K EDGAR
  11. May 15, 2026SCHEDULE 13G/A EDGAR
  12. May 5, 202610-Q EDGAR
  13. May 5, 20268-K EDGAR
  14. Apr 30, 20264/A EDGAR
  15. Apr 30, 20264/A EDGAR
  16. Apr 29, 20264 EDGAR
  17. Apr 29, 20264 EDGAR
  18. Apr 29, 2026ARS EDGAR
  19. Apr 29, 2026DEFA14A EDGAR
  20. Apr 29, 2026DEF 14A EDGAR

The 269 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

50 open-market trades by officers, directors and large owners since October 2021: 43 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 24, 2026Lerner NeilChief Accounting OfficerBuy2,500$1.14$2.9KForm 4
Apr 29, 2026Lerner NeilChief Accounting OfficerBuy15,000$1.89$28.4KForm 4
Apr 29, 2026Anderman JonathanGeneral CounselBuy25,000$1.89$47.2KForm 4
May 27, 2025Schuetz Thomas J.CHIEF EXECUTIVE OFFICERBuy10,000$2.11$21.1KForm 4
Apr 9, 2025GORDON CARL LDirectorSale3,571,428$1.59$5.7MForm 4
Apr 9, 2025OrbiMed Capital GP VI LLCDirectorSale3,571,428$1.59$5.7MForm 4
Apr 7, 2025Anderman JonathanGeneral CounselBuy20,000$1.54$30.8KForm 4
Apr 7, 2025Lerner NeilChief Accounting OfficerBuy20,000$1.42$28.4KForm 4
Mar 10, 2023Schuetz Thomas J.CHIEF EXECUTIVE OFFICERBuy10,000$3.37$33.7KForm 4
Feb 27, 2023Schuetz Thomas J.CHIEF EXECUTIVE OFFICERBuy20,000$3.98$79.6KForm 4
Feb 15, 2023Schuetz Thomas J.CHIEF EXECUTIVE OFFICERBuy20,000$3.86$77.2KForm 4
Jan 31, 2023Schuetz Thomas J.CHIEF EXECUTIVE OFFICERBuy20,000$4.05$81.0KForm 4
Jan 24, 2023Schuetz Thomas J.CHIEF EXECUTIVE OFFICERBuy20,000$4.19$83.8KForm 4
Nov 25, 2022Bisker-Leib VeredCHIEF EXECUTIVE OFFICERSale2$4.36$9Form 4
Nov 23, 2022Bisker-Leib VeredCHIEF EXECUTIVE OFFICERSale9,569$4.30$41.1KForm 4
Nov 22, 2022Bisker-Leib VeredCHIEF EXECUTIVE OFFICERSale14,929$4.19$62.6KForm 4
Nov 21, 2022Bisker-Leib VeredCHIEF EXECUTIVE OFFICERSale16,035$4.34$69.6KForm 4
Nov 18, 2022Bisker-Leib VeredCHIEF EXECUTIVE OFFICERSale6,226$4.40$27.4KForm 4
Nov 8, 2022ORBIMED ADVISORS LLCDirectorBuy402,000$3.21$1.3MForm 4
Nov 8, 2022GORDON CARL LDirectorBuy402,000$3.21$1.3MForm 4

All 50 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Tang Capital Management LLC17,990,782$39.4M1.8%+1,199,973
Orbimed Advisors LLC15,219,994$33.3M0.6%No change
Montanova Capital, LLC14,101,159$30.9M0.6%−206,220
BlackRock, Inc.11,281,781$24.7M0.0%+1,775,701
State Street Corp9,953,653$21.8M0.0%+3,258,677
Enavate Sciences Gp, LLC7,788,150$17.1M4.9%No change
Vivo Capital, LLC7,757,060$17.0M1.6%−1,788,406
Vanguard Capital Management LLC6,118,782$13.4M0.0%+81,607
Palo Alto Investors LP5,831,813$12.8M1.8%+4,317,309
Millennium Management LLC4,713,247$10.3M0.0%+3,867,027
Geode Capital Management, LLC3,815,189$8.4M0.0%+249,419
Vanguard Portfolio Management LLC3,771,032$8.3M0.0%+2,688,381
Qube Research & Technologies Ltd3,687,489$8.1M0.0%+1,137,133
Blue Owl Capital Holdings LP3,624,076$7.9M1.2%+682,551
Citadel Advisors LLC3,570,674$7.8M0.0%+2,849,264
Goldman Sachs Group Inc3,531,000$7.7M0.0%+1,535,606
Rock Springs Capital Management LP3,524,929$7.7M0.4%+219,621
Aqr Capital Management LLC3,509,137$7.7M0.0%+3,308,709
Birchview Capital, LP1,675,000$3.7M1.7%+209,133
Kingdon Capital Management, L.l.c.1,400,000$3.1M0.4%New
Fisher Asset Management, LLC1,391,890$3.0M0.0%+43,631
Royce & Associates LP1,336,780$2.9M0.0%−283,018
Fmr LLC1,212,196$2.7M0.0%−589,525
Adage Capital Partners Gp, L.l.c.1,186,500$2.6M0.0%−7,300,000
Northern Trust Corp1,140,914$2.5M0.0%+92,356

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51